National Institutes of Health
Fellowship
University of Zurich
Fellowship
New York Presbyterian Hospital
Residency
New York Presbyterian Hospital
Internship
University of Heidelberg Medical School
MD
Multi-institutional development and testing of attention-enhanced deep learning segmentation of thyroid nodules on ultrasound.
Multi-institutional development and testing of attention-enhanced deep learning segmentation of thyroid nodules on ultrasound. Int J Comput Assist Radiol Surg. 2025 Feb; 20(2):259-267.
PMID: 39751996
Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor.
Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor. J Clin Endocrinol Metab. 2024 Dec 18; 110(1):263-274.
PMID: 38817124
Adolescent Hyperparathyroidism: An Updated Contemporary Surgical Experience at a Tertiary Center.
Adolescent Hyperparathyroidism: An Updated Contemporary Surgical Experience at a Tertiary Center. J Surg Res. 2025 Jan; 305:150-155.
PMID: 39693848
Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence.
Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence. J Clin Endocrinol Metab. 2024 Oct 15; 109(11):2729-2734.
PMID: 38651609
Evaluating the clinical performance of an updated microRNA classifier in indeterminate and RAS-mutated thyroid nodule management: A multi-institutional study.
Evaluating the clinical performance of an updated microRNA classifier in indeterminate and RAS-mutated thyroid nodule management: A multi-institutional study. Surgery. 2025 01; 177:108833.
PMID: 39394019
Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors.
Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2025 01; 177:108834.
PMID: 39395860
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy.
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
PMID: 39093924
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors.
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors. Cancers (Basel). 2024 Aug 28; 16(17).
PMID: 39272851
Clinical Significance of Pheochromocytoma Size on the Timing and Extent of Surgery.
Clinical Significance of Pheochromocytoma Size on the Timing and Extent of Surgery. J Surg Res. 2024 Jun; 298:88-93.
PMID: 38593602
Diagnostics and Imaging for Pancreatic Neuroendocrine Tumors.
Diagnostics and Imaging for Pancreatic Neuroendocrine Tumors. Surg Clin North Am. 2024 Aug; 104(4):883-890.
PMID: 38944506